Search clinical trials for: MTG201

Total 51 results

UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
UNION therapeutics

Completed

Sensitization Study of ATx201 in Healthy Volunteers

Sensitivity, Contact

United States
UNION therapeutics

Completed

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Impetigo

South Africa
UNION therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis

Canada
UNION therapeutics

Completed

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Irritation Potential of Topic Agent

United States
Aevi Genomic Medicine, LLC, a Cerecor company
Medgenics Medical Israel Ltd.

Terminated

TARGTEPO Treatment for Anemia in PD US Trial

Anemia of End Stage Renal Disease

United States
Grit Biotechnology

Recruiting

GT201 Injection For The Treatment Of Advanced Solid Tumors

Solid Tumor, Adult

China
Grit Biotechnology

Recruiting

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Solid Tumor

China
Shanghai Miracogen Inc.

Recruiting

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

China
RenJi Hospital

Recruiting

Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors

Solid Tumor

China
Grit Biotechnology

Recruiting

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors (GT201)

Solid Tumor

China
Jetema USA Inc.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Glabellar Lines
Mthera Pharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease

Parkinson's Disease
Medy-Tox

Completed

Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Submental Fat

Korea, Republic of
Medy-Tox

Completed

A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Submental Fat

Korea, Republic of
Aevi Genomic Medicine, LLC, a Cerecor company
Medgenics Medical Israel Ltd.

Completed

TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)

End Stage Renal Disease | Chronic Kidney Disease

Israel
Takeda

Completed

Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis

Plaque Psoriasis

Canada
Aevi Genomic Medicine, LLC, a Cerecor company
Medgenics Medical Israel Ltd.

Terminated

TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)

Anemia of End Stage Renal Disease

Israel
Bayer
Ultragenix pharmaceutical

Active, not recruiting

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

Hemophilia A

Netherlands, United States, Germany, United Kingdom, France, Bulgaria
Grit Biotechnology

Recruiting

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

Adult | Gynecological Tumors

China
Takeda

Completed

Single-Dose Study of MT203

Healthy Volunteers

Japan
Mthera Pharma Co., Ltd.
Amarex Clinical Research

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

Parkinson's Disease

United States
Momotaro-Gene Inc.
Baylor College of Medicine; Synteract, Inc.

Active, not recruiting

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Malignant Pleural Mesothelioma

United States
Grit Biotechnology

Recruiting

GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Adult

China
Fudan University
The Hong Kong Polytechnic University

Completed

Transcranial Alternating Current Stimulation

Stroke

China
Medy-Tox

Completed

Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects

Healthy Volunteers

Korea, Republic of
Translate Bio, Inc.

Withdrawn

Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency (STEP-OTC)

Ornithine Transcarbamylase Deficiency
UNION therapeutics

Completed

Evaluation of ATx201 as a Topical Antibiotic Agent

Infection, Bacterial

Austria
Helixmith Co., Ltd.

Completed

Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis

Osteoarthritis of the Knee
PhytoTech Therapeutics, Ltd.

Unknown

Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms

Multiple Sclerosis

Israel
Kitasato University
Aetas Pharma Co. Ltd.

Unknown

First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation

Paroxysmal Atrial Fibrillation

Japan
Yuji KUMAGAI
Aetas Pharma Co. Ltd.

Completed

First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects

Healthy Volunteers

Japan
Kitasato University
Aetas Pharma Co. Ltd.

Completed

Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects

Healthy Volunteers

Japan
Oslo University Hospital
Targovax ASA

Recruiting

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

Multiple Myeloma | Smoldering Multiple Myeloma

Norway
Tragara Pharmaceuticals, Inc.

Completed

Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients

Non-small Cell Lung Cancer

United States
Inmunotek S.L.
BioClever 2005 S.L.; NTS hub S.L

Terminated

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

Perennial Allergic Rhinitis | Allergic Rhinoconjunctivitis | House Dust Mite Allergy | Pollen Allergy

Spain
Takeda

Completed

A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis (PRIORA)

Rheumatoid Arthritis

Bulgaria, Netherlands
Inmunotek S.L.

Recruiting

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Rhinitis, Allergic | Rhinoconjunctivitis | Asthma, Allergic

Spain
University of Kansas Medical Center
Targovax ASA

Not yet recruiting

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA)

Pancreas Cancer

United States
CuraVac
University Hospital, Antwerp; Aepodia

Withdrawn

A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis

Myasthenia Gravis, Generalized

Belgium
CuraVac
University Hospital, Antwerp; Leiden University Medical Center; Aepodia

Completed

Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis

Myasthenia Gravis

Belgium
Targovax ASA

Completed

Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

Pancreatic Cancer, Resected

Norway, Spain, United Kingdom
Inmunotek S.L.

Recruiting

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

Rhinitis, Allergic | Rhinoconjunctivitis | Asthma, Allergic

Spain
Assembly Biosciences

Terminated

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Mild

United States, Canada
Forest Laboratories

Completed

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Amgen Research (Munich) GmbH

Completed

Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases (MT201-204)

Colorectal Cancer | Liver Metastases

Germany, France
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
Forest Laboratories

Completed

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
TransDerm, Inc.
Pachyonychia Congenita Project

Completed

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)

Pachyonychia Congenita

United States
PMG Pharm Co., Ltd

Completed

Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients

Osteoarthritis of the Knee

Korea, Republic of

3

Subscribe